Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of SPYK04 monotherapy in advanced or metastatic solid tumors
jRCT2080225265Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of spyk04 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and ovarian cancer (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Jul 2020; status: completed.
02
Drugs
spyk04
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on jRCT2080225265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225265.